Another phase-2, two-arm, open-label clinical trial (NCT03003520) is ongoing to evaluate the safety, activity, and predictive biomarkers of durvalumab in combination with chemoimmunotherapy (R-CHOP) or lenalidomide plus R-CHOP, followed by Durvalumab consolidation therapy, in previously untreated subjects with DLBCL. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.